Obesity Treatment Drugs: Weighing the Benefits and Risks
The Rise of GLP-1 Receptor Agonist Drugs for Weight Loss
Glucagon-like peptide-1 receptor agonist (GLP-1 Receptor Agonist·GLP-1RA) drugs have gained popularity for their effectiveness in treating obesity. As a result, many people are turning to these medications for weight loss purposes.
Celebrities like Elon Musk, Kim Kardashian, and Adele have reportedly used obesity treatment drugs like WeGobee to shed pounds, inspiring others to follow suit.
Understanding GLP-1 and its Effects on the Body
GLP-1 is a hormone that mimics the satiety hormone released from the intestines when eating. It suppresses appetite by making you feel full even when consuming less food.
This effect has led to the development of GLP-1RA drugs, which have been shown to reduce body weight by more than 15% in 3 to 6 months when injected once a week.
Potential Risks and Side Effects of GLP-1RA Drugs
A recent case in Japan highlights the potential risks associated with GLP-1RA drugs. A 30-year-old woman developed abdominal pain after eating kelp and seafood while taking semaglutide, a GLP-1 drug, and had to undergo surgery to remove a portion of her small intestine.
Researchers emphasize that GLP-1RA reduces the motility of the small intestine, which can increase the risk of intestinal obstruction, particularly when consuming foods like seaweed that are not easily digested.
